Clinical trial NCT04679753: Brainsway DTMS for Treatment of MDD Using iTBS
Official title: Brainsway Deep TMS System for Treatment of Major Depressive Disorder (MDD) Using Intermittent Theta Burst Stimulation (iTBS) Protocol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Major Depressive Disorder
Keywords: intermittent Theta Burst Stimulation
iTBS
Depression
Lead sponsor: Brainsway
Sponsor class: INDUSTRY
First posted: 2020-12-22
Enrollment: 177
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Brainsway Deep TMS with intermittent Theta Burst Stimulation (iTBS)
Primary purpose: TREATMENT

Brief summary: The safety and effectiveness of the BrainsWay deep transcranial magnetic stimulation (DTMS) device for the intended use of Major Depressive Disorder (MDD) using the intermittent theta-burst (iTBS) stimulation protocol will be evaluated in a non-inferiority study, comparing the iTBS treatment with the FDA cleared, (510(k) No. K122288) Brainsway DTMS device to the High Frequency (HF) protocol using the same device.

Detailed description: The purpose of the study is to evaluate the safety and efficacy of Brainsway Deep TMS for the treatment of Major Depressive Disorder using the iTBS stimulation protocol, by comparing it to clinical data collected in the Brainsway randomized, controlled Multicenter study (CTP-001-00), using the HF DTMS stimulation protocol used in support of the Brainsway DTMS device 510(k) K122288.

In the post-marketing study, patients will be treated with an intermittent theta burst (iTBS) protocol, using the same Brainsway DTMS device with the same H1-Coil. Furthermore, the treatment paradigm is the same, consisting of TMS sessions performed daily for 5 weeks (20 DTMS sessions). The iTBS stimulation protocol consists of bursts of 3 pulses at 50 Hz, 5 Hz bursts frequency, 2s on and 8s off, 600 pulses per session. The HF stimulation protocol was delivered at 18 Hz, 120% stimulation intensity of the resting MT, 55 trains of 2s duration, inter-train interval (ITI) of 20s, for 1980 pulses per session.

The clinical study design includes multiple measurements of safety and effectiveness parameters.

The primary outcome measure is the change from baseline in HDRS-21 scores at the 5 week visit (after 20 treatment sessions). The success criteria of the study is a non-inferiority margin of 3.0 points.

The secondary efficacy endpoints of the study include evaluation of the response and remission rates, based on HDRS-21 scores, at the 5 week visit, change in CGI-S score from baseline to 6 weeks and response and remission rates based on CGI-S scores at the 6 week visit.

Safety will be assessed at each treatment visit. Patients will be asked to report any adverse event since their previous visit.

Eligibility criteria: Inclusion Criteria:

* Outpatients
* Diagnosis of Major Depression Disorder

Exclusion Criteria:

* Other significant Axis I psychiatric disorder with greater impairment than MDD

Primary outcomes:
measure: The primary outcome measure was the change from baseline in HDRS-21 scores at the 5 week visit.
timeFrame: 5 weeks
Secondary outcomes:
measure: HDRS-21 Response and Remission rates
timeFrame: 5 weeks
measure: Change in CGI-S score from baseline at the 6 week visit
timeFrame: 6 weeks
measure: CGI-S Response and Remission rates
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Yorkton
country: Canada
facility: SynapseTMS
state: Saskatchewan
Study officials:
affiliation: SynapseTMS
name: Oluremi Adefolarin, MD
role: PRINCIPAL_INVESTIGATOR
References: